CSS LLC’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

CSS LLC’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-452,700	Closed	-$26.6M	–	1007
2023 Q4	$26.6M	Buy	+452,700	New	+$25.5M	1.54%	13
2022 Q4	–	Sell	-4,800	Closed	-$335K	–	1165
2022 Q3	$335K	Buy	4,800 +2,000	+71%	+$148K	0.02%	634
2022 Q2	$188K	Buy	+2,800	New	+$178K	0.01%	812
2021 Q4	–	Sell	-3,900	Closed	-$690K	–	1360
2021 Q3	$690K	Buy	3,900 +3,500	+875%	+$563K	0.03%	532
2021 Q2	$65K	Hold	400	–	–	﹤0.01%	972
2021 Q1	$69K	Buy	+400	New	+$79.2K	﹤0.01%	857

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

CSS LLC's MRTX Position: Q1 2024 in Review

CSS LLC sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 343,845 shares — an estimated $20.2M sold.

CSS LLC first reported a position in MRTX in Q1 2021 and held it in 5 quarters. The position peaked at $20.2M in Q4 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

CSS LLC reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
CSS LLC sold 343,845 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $20.2M.
CSS LLC first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
CSS LLC's Mirati Therapeutics, Inc. Common Stock position peaked at $20.2M in Q4 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on CSS LLC's 13F filing for Q1 2024, filed 15 May 2024.